Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October
September 19, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference
August 28, 2018 08:00 ET
|
Spero Therapeutics, Inc.
Highlights include eleven presentations covering SPR994’s pharmacokinetics and pharmacodynamics, SPR206’s broad spectrum of activity and favorable toxicology, and urinary tract infection epidemiology ...
Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors
August 14, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview
August 09, 2018 16:10 ET
|
Spero Therapeutics, Inc.
Pipeline continues to advance following recent positive data from SPR994 and Potentiator Platform; SPR994 Phase 3 initiation on-track to initiate around year-endRecent Follow-on Offering and BARDA...
Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
July 16, 2018 06:59 ET
|
Spero Therapeutics, Inc.
Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994Planned pivotal Phase 3 trial of SPR994 on track to initiate around...
Spero Therapeutics Announces Pricing of Securities Offering
July 12, 2018 20:10 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Proposed Offering of Common Stock
July 09, 2018 16:10 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
July 09, 2018 07:30 ET
|
Spero Therapeutics, Inc.
Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending dosesData support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to...
Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018
June 05, 2018 08:00 ET
|
Spero Therapeutics, Inc.
Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’s broad spectrum of activity and equivalence to IV carbapenems CAMBRIDGE, Mass., June 05, 2018 ...
Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June
June 01, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...